Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia.
Campillo-Gimenez L, Assoumou L, Valantin MA, Pajanirassa P, Villemonteix J, Soulié C, Marcelin AG, Costagliola D, Capeau J, Autran B, Katlama C, Guihot A; ROCnRAL ANRS 157 Study Group.
Campillo-Gimenez L, et al. Among authors: capeau j.
AIDS. 2015 Apr 24;29(7):853-6. doi: 10.1097/QAD.0000000000000626.
AIDS. 2015.
PMID: 25719828